HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.

Abstract
We have previously reported reversible hypogonadism induced by the intranasal administration of the luteinizing hormone-releasing hormone agonist buserelin as a new therapeutic approach for endometriosis. Thirteen patients were randomized to receive intranasal buserelin (400 micrograms 3 times a day) or subcutaneous buserelin injection (200 micrograms once daily) for a 6- to 9-month period. Both routes of administration were effective in inhibiting serum estradiol levels to near the menopausal range after 1 month of treatment. The two dosage regimens had also a comparable efficacy in alleviating endometriosis symptoms and in reducing the revised American Fertility Society scoring at laparoscopic examination. The implant score mainly decreased by more than 70%. The occurrence of side effects was similar in both groups, and side effects were mainly hot flushes, dyspareunia secondary to decreased vaginal secretion, and decreased libido. Results of hemogram, urinalysis, and serum biochemical and hormonal tests remained in the normal range. The ovulatory cycle rapidly returned after the cessation of treatment, and three pregnancies occurred in six previously infertile patients. Intranasal and subcutaneous buserelin were well accepted and equally effective in inhibiting the pituitary-ovarian function, which caused mild menopausal symptoms but an important regression of endometriosis.
AuthorsA Lemay, R Maheux, C Huot, J Blanchet, N Faure
JournalAmerican journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 158 Issue 2 Pg. 233-6 (Feb 1988) ISSN: 0002-9378 [Print] United States
PMID3124618 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Buserelin
Topics
  • Administration, Intranasal
  • Adult
  • Buserelin (administration & dosage, therapeutic use)
  • Endometriosis (drug therapy)
  • Estradiol (blood)
  • Female
  • Follicle Stimulating Hormone (blood)
  • Humans
  • Injections, Subcutaneous
  • Luteinizing Hormone (blood)
  • Ovary (drug effects)
  • Pelvic Neoplasms (drug therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: